Cipla Ltd, one of India’s leading pharmaceutical companies, is in advanced talks to sell a controlling stake in the company. The potential buyers include two consortiums: one led by Torrent Pharmaceuticals Ltd and the other by a group of buyout firms led by BPEA EQT and General Atlantic. Let us understand the details of these discussions, the motivations behind the sale, and the potential implications for Cipla.
The Bidders
1) Torrent Pharmaceuticals Ltd Consortium – The Mehta family, the promoters of Torrent Pharma, back this consortium. The investment also involves entities associated with Sun Pharmaceutical Industries Ltd., led by Dilip Shanghvi, and Zydus Lifesciences Ltd., owned by the Patel family. This bid would make Torrent Pharma the second-largest Indian drugmaker after Sun Pharma.
2) Buyout Firms Consortium (BPEA EQT and General Atlantic) – This group of buyout firms is looking to acquire a controlling stake in Cipla. Their takeover plan involves a direct cash deal for the Hamied family’s stake in the company and investments from emerging market funds managed by these global private equity giants. Other private equity firms may join the consortium to fulfil the financial requirements of the deal.
The Valuation
Cipla’s promoters, led by Yusuf K. Hamied, seek a valuation of at least ₹33,000 crore for their 33.47% stake. They will only cede control if binding bids value the company at ₹1 trillion. The promoters are looking for a price of a little over ₹1,200 per share, while Cipla’s shares were trading at ₹1,180.50 at the time of this report, valuing the company at ₹95,300 crore.
Implications of the Sale
1) Mandatory Open Offer – Any change in promoter control will trigger a mandatory open offer, requiring the buyer to offer to acquire as much as 26% from Cipla’s shareholders. It could significantly increase the size of the deal, reaching $7 billion or more if a premium is offered to public shareholders.
2) Partial Retention of Ownership – It’s anticipated that one or two members of Cipla’s promoter family may retain about 5% of the company as non-promoter shareholders even after the proposed promoter exit.
3) Reasons for the Sale – According to investment bankers, the sale has been driven by a need for clear successors within the Hamied family to run Cipla. It underscores the importance of succession planning in family-owned businesses.
4) Legacy and Social Impact – Cipla has a rich legacy of manufacturing and supplying affordable generic drugs, contributing significantly to healthcare access in India and other countries. This legacy makes the sale a matter of political, economic, and social interest.
5) Blackstone’s Exit – US-based Blackstone was initially in discussions to acquire Cipla but withdrew due to criticism from confident political leaders who viewed Cipla as an integral part of India’s history.
Summary
The potential sale of a controlling stake in Cipla to either the Torrent Pharmaceuticals consortium or the buyout firms led by BPEA EQT and General Atlantic represents a significant development in the pharmaceutical industry. The outcome of these discussions will have substantial implications for Cipla’s future and the pharmaceutical industry in India and beyond. It remains to be seen how this story unfolds and its impact on the legacy and social responsibility of Cipla in the healthcare sector.
Disclaimer: We do not endorse or encourage you to take trades or investment decisions based upon our posts/research, all of your trading and investment activities are your own and should be taken through consultation with reputed financial advisors. The analysis posted on this website has been created by involving multiple mediums which are present over the Internet.